Navigation Links
Stopping the worm from turning
Date:6/4/2013

Despite the clear arguments for controlling parasitic infections, we know surprisingly little about the developmental processes in parasitic nematodes. A good model system for research is provided by Oesophagostomum dentatum, a roundworm which infects the large intestines of pigs, slowing the animals' growth and leading to significant economic losses. A number of chemicals are available to help keep the parasite in check but the worms are growing increasingly resistant to their use and so there is a substantial need for new methods of treatment.

From eggs to parasites

The worm, Oesophagostomum dentatum, has a fairly simple life cycle. Eggs appear in the faeces around 3 weeks after ingestion of third-stage larvae, the so called L3 stage larvae. In the first two developmental stages, the larvae are not infective. The third-stage larvae migrate from the faeces into the surroundings, where they can again be ingested by pigs. When the parasite reaches the large intestine, the third-stage larvae burrow into the mucosal layer of the intestinal wall and moult to fourth-stage larvae. After a further 6-17 days they emerge from the mucosa and undergo a final moult before they mature into adults and reproduce.

Drug screen on worm proteins

Together with colleagues in Australia and the USA, Martina Ondrovics in the group of Anja Joachim at the University of Veterinary Medicine, Vienna (Vetmeduni) has undertaken a detailed in vitro investigation of the proteins involved in the transition from third-stage to fourth-stage larvae. The researchers employed an integrative approach that combined in vitro drug testing with proteomic and bioinformatic analysis. Previous work had identified a number of enzymes (hydrolases) that are likely to have a role in parasite development. Ondrovics used sophisticated techniques to examine the effects of certain compounds (enzyme inhibitors) on the larval protein composition.

Searching for functionality

Four of the seven enzyme inhibitors she tested were found to inhibit the development of L3 larvae. The inhibitors also caused substantial alterations in the amounts of certain proteins in the larvae. Ondrovics found that 22 proteins were expressed at significantly different levels. Although no functions could be assigned to three of the proteins, bioinformatics analysis suggested that the remainder are involved in a wide range of biological processes, including reproduction, cellular metabolic processes, multicellular organismal growth, developmental processes, growth, locomotion, response to stimuli, localization and biological regulation. It seems that the activities of these proteins are increased at the L3 to L4 transition, so the proteins are likely to have key functions at this time.

Designing new weapons against parasites

A better understanding of key developmental processes could enable new strategies to control parasitic nematodes based on the disruption of key biological pathways. The work at the Vetmeduni thus paves the way for future research to develop drugs that act specifically against parasitic nematodes. As Ondrovics says, "We urgently need new targets for intervention: the worms are rapidly becoming resistant to all the weapons at our disposal. The proteins we identified seem to be involved in fundamental developmental processes and we hope that functional studies will show that some of them are ideal candidate targets for the design of new and selective inhibitors."


'/>"/>

Contact: Martina Ondrovics
martina.ondrovics@vetmeduni.ac.at
43-125-077-2218
University of Veterinary Medicine -- Vienna
Source:Eurekalert

Related biology news :

1. Einstein study reveals new approach for stopping herpes infections
2. Stopping smoking reduces risk of bacterial pneumonia in people with HIV
3. Stopping flies before they mature
4. Turning human stem cells into brain cells sheds light on neural development
5. Returning military personnel to duty following severe injury to the lower extremity
6. Researchers find molecular switch turning on self-renewal of liver damage
7. AZTI-Tecnalia is turning vegetable by-products destined for landfills into feedstuff
8. Zebrafish may hold the answer to repairing damaged retinas and returning eyesight to people
9. Why astronauts experience low blood pressure after returning to Earth from space
10. Turning ideas into products faster
11. Turning down the dial: Ocean energy development with less sound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
Breaking Biology Technology: